An evaluation of the emergence of drug resistant virus for HIV/AIDS drug treatments

HIV/AIDS drug treatment, such as highly active anti-retroviral therapy (HAART), often fails due to the emergence of drug resistant species. In this paper we investigate a new estimation method for the possibility of emergence of drug resistant mutation. To the best knowledge of the author this work...

Full description

Saved in:
Bibliographic Details
Published in2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) Vol. 2015; pp. 3258 - 3261
Main Author Chang, Hyuk-Jun
Format Conference Proceeding Journal Article
LanguageEnglish
Published United States IEEE 01.08.2015
Subjects
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - therapeutic use
Computer Simulation
Dose-Response Relationship, Drug
Drug Resistance, Viral - genetics
Drugs
HIV Infections - drug therapy
HIV Infections - virology
Human immunodeficiency virus
Humans
Immune system
Mathematical model
Mutation
Strain
Switches
Online AccessGet full text

Cover

More Information
Summary:HIV/AIDS drug treatment, such as highly active anti-retroviral therapy (HAART), often fails due to the emergence of drug resistant species. In this paper we investigate a new estimation method for the possibility of emergence of drug resistant mutation. To the best knowledge of the author this work is the first study to try to describe quantitatively the possibility of drug resistance emergence for HIV/AIDS drug treatments. In simulation studies we compare HIV/AIDS treatment methods, such as structured treatment interruption (STI) and improved gradual dosage reduction (iGDR), based on the proposed analysis. From the analysis we can explain why STI treatment often fails and also can show that iGDR is desirable rather than STI particularly in terms of the decrease of the possibility of emergence of drug resistant virus.
ISSN:1094-687X
1557-170X
DOI:10.1109/EMBC.2015.7319087